Open AccessDrug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
Author(s) -
Jingjun Huang,
Wensou Huang,
Meixiao Zhan,
Yongjian Guo,
Liang Li,
Mingyue Cai,
Lin Li,
Mian He,
Hui Lian,
Ligong Lu,
Kangshun Zhu
Publication year - 2021
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s339379
Subject(s) - medicine , hepatocellular carcinoma , oxaliplatin , folfox , gastroenterology , chemotherapy , fluorouracil , response evaluation criteria in solid tumors , adverse effect , colorectal cancer , cancer , progressive disease
To evaluate the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with oxaliplatin plus fluorouracil and leucovorin (FOLFOX)-based hepatic arterial infusion chemotherapy (D-TACE-HAIC) for unresectable large (5.1-10 cm) or huge (>10 cm) hepatocellular carcinoma (HCC).